Rapamycin and Testosterone Interaction: Monitor | Peptide Database

Join others researching Nandrolone — share findings, ask questions, and learn from real experiences Nandrolone is a synthetic 19-nortestosterone anabolic-androgenic steroid that has been in clinical use since the 1960s. Structurally, it differs from testosterone by the absence of a methyl group at the C19 position, which significantly reduces its androgenic activity relative to its anabolic potency. Nandrolone decanoate (Deca-Durabolin) was FDA-approved for the treatment of anemia associated with chronic renal failure and has also been used clinically for osteoporosis, wasting diseases, and severe burn recovery. Among anabolic steroids, nandrolone is particularly valued for its positive effects on collagen synthesis, joint health, and bone mineral density. It has one of the most favorable anabolic-to-androgenic ratios of any synthetic steroid (approximately 125:37 compared to testosterone at 100:100), making it a frequent choice for individuals seeking muscle growth with reduced androgenic side effects. Nandrolone is available in two primary ester formulations: the long-acting decanoate ester and the shorter-acting phenylpropionate ester (NPP). Nandrolone binds to the androgen receptor (AR) with affinity comparable to testosterone, promoting nitrogen retention, protein synthesis, and satellite cell activation in skeletal muscle tissue. Its anabolic effects are mediated through AR-dependent gene transcription that upregulates muscle-specific proteins including myosin heavy chain and IGF-1. A key distinguishing feature of nandrolone is its interaction with 5-alpha reductase: unlike testosterone, which is converted to the more potent androgen dihydrotestosterone (DHT), nandrolone is reduced to dihydronandrolone (DHN), a weaker androgen. This results in lower androgenic activity in tissues rich in 5-alpha reductase (skin, prostate, hair follicles). Nandrolone also stimulates collagen synthesis and bone mineral content through direct effects on osteoblasts and fibroblasts, contributing to its well-documented benefits for joint and connective tissue health. It exhibits moderate progestogenic activity, binding to the progesterone receptor at approximately 20% the affinity of progesterone, which can influence prolactin levels and contribute to progesterone-related side effects. Nandrolone aromatizes to estradiol at roughly 20% the rate of testosterone, resulting in lower but not absent estrogenic activity.

FDA-approved for promoting weight regain following involuntary weight loss due to major surgery. Oxandrolone accelerates lean mass recovery and improves nitrogen balance during the recovery period. Extensively studied in severe burn patients, where oxandrolone reduces protein catabolism, accelerates wound healing, shortens hospital stays, and improves long-term lean body mass outcomes. Widely used in major burn centers. Effective for reversing muscle wasting and weight loss in patients with HIV/AIDS. Increases lean body mass and improves functional capacity in wasting syndrome. FDA-approved indication for weight recovery after chronic infections that result in significant involuntary weight loss. Counteracts catabolic effects of prolonged corticosteroid therapy by enhancing nitrogen retention and protein synthesis, helping preserve lean mass during necessary glucocorticoid treatment. FDA-approved for relief of bone pain accompanying osteoporosis. Increases bone mineral density and reduces pain scores in osteoporotic patients, particularly postmenopausal women. Used as adjunctive therapy with growth hormone in girls with Turner syndrome to improve final adult height. Clinical trials show additive benefit when combined with GH therapy. Promotes nitrogen retention and anti-catabolic effects during energy restriction, preserving lean tissue while facilitating fat loss. Commonly used during cutting phases. Increases muscular strength through enhanced protein synthesis and creatine phosphate regeneration, without the water retention associated with aromatizing compounds. Clinical studies have demonstrated selective reduction in abdominal and visceral adipose tissue with oxandrolone treatment, independent of total caloric intake changes.